Analysts Set Candel Therapeutics, Inc. (NASDAQ:CADL) Price Target at $18.33

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) have been given an average recommendation of “Moderate Buy” by the eight ratings firms that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $17.00.

Several equities research analysts have issued reports on the stock. Citigroup lowered their price objective on shares of Candel Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a report on Wednesday, January 21st. Zacks Research downgraded Candel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, January 19th. Stephens reiterated an “overweight” rating and issued a $15.00 target price on shares of Candel Therapeutics in a report on Monday, December 8th. Finally, Wall Street Zen lowered Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th.

Candel Therapeutics Stock Up 1.8%

Shares of CADL opened at $5.18 on Friday. The firm has a fifty day moving average price of $5.78 and a 200-day moving average price of $5.51. The company has a current ratio of 8.25, a quick ratio of 8.25 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $284.38 million, a P/E ratio of -9.09 and a beta of -0.94. Candel Therapeutics has a 12-month low of $4.25 and a 12-month high of $9.21.

Institutional Investors Weigh In On Candel Therapeutics

Several large investors have recently modified their holdings of CADL. BNP Paribas Financial Markets boosted its stake in shares of Candel Therapeutics by 128.2% during the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock valued at $40,000 after purchasing an additional 4,439 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Candel Therapeutics during the fourth quarter worth $51,000. Tower Research Capital LLC TRC boosted its position in Candel Therapeutics by 361.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock valued at $49,000 after acquiring an additional 7,527 shares in the last quarter. Invesco Ltd. purchased a new position in shares of Candel Therapeutics in the 1st quarter valued at $59,000. Finally, ProShare Advisors LLC purchased a new position in shares of Candel Therapeutics in the 4th quarter valued at $59,000. Institutional investors own 13.93% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.